Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder. Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. The present study evaluates the ability of peptide corresponding to the NF-κB essential modifier-binding domain (NBD) of IκB kinase α (IKKα) or IKKβ to prevent nigrostriatal degeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD and establish a role for NF-κB in human parkinsonism. First, we found that NF-κB was activated within the substantia nigra pars compacta of PD patients and MPTP-intoxicated mice. However, i.p. injection of wild-type NBD peptide reduced nigral activation of NF-κB, suppressed nigral microglial activation, protected both the nigrostriatal axis and neurotransmitters, and improved motor functions in MPTP-intoxicated mice. These findings were specific because mutated NBD peptide had no effect. We conclude that selective inhibition of NF-κB activation by NBD peptide may be of therapeutic benefit for PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Self-citationNF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Self-citationWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
González-Scarano, F., & Baltuch, G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.219 · Cited by 984
Eng, L. F., & Ghirnikar, R. S. (1994) · Brain Pathology · doi:10.1111/j.1750-3639.1994.tb00838.x · Cited by 864
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984) · Nature · doi:10.1038/311464a0 · Cited by 786
Research works printed but not linked: 2
- T Nagatsu, M Mogi, H Ichinose, A Togari J Neural Transm 60, 277–290 (2000).
- 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q · doi:10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q
Cited by
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review
Shih, R.-H., Wang, C.-Y., & Yang, C.-M. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00077 · Cited by 910
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response
Bachiller, S., Jiménez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., & Boza-Serrano, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00488 · Cited by 707
NF-κB inhibition delays DNA damage–induced senescence and aging in mice
Tilstra, J. S., Robinson, A. R., Wang, J., Gregg, S. Q., Clauson, C. L., Reay, D. P., Nasto, L. A., St Croix, C. M., Usas, A., Vo, N., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45785 · Cited by 462
Bazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441
“Nuclear translocation of NF-κBp65 in dopaminergic neurons of PD mice (72) has been reported to target microglia in the SNpc associated with COX-2 expression and prostaglandin E2 production (207).”
BackgroundAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Cellular Specificity of NF-κB Function in the Nervous System
Dresselhaus, E. C., & Meffert, M. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01043 · Cited by 345
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Chronic stress and glucocorticoids: From neuronal plasticity to neurodegeneration
Vyas, S., Rodrigues, A. J., Silva, J. M., Tronche, F., Almeida, O. F. X., Sousa, N., & Sotiropoulos, I. (2016) · Neural Plasticity · doi:10.1155/2016/6391686 · Cited by 297
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Increased levels of NF-κB are observed in tyrosine hydroxylase (TH) and dopaminergic neurons, astrocytes and microglia, with implications on the pathogenesis of PD; while inhibition of NF-κB is correlated with neuroprotective effects in such PD models (299, 300).”
BackgroundHarischandra, D. S., Ghaisas, S., Zenitsky, G., Jin, H., Kanthasamy, A., Anantharam, V., & Kanthasamy, A. G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00654 · Cited by 291
Singh, S., & Singh, T. G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200207120949 · Cited by 291
Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy
Qian, L., Flood, P. M., & Hong, J.-S. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0428-1 · Cited by 287
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
The IκB kinase complex: master regulator of NF-κB signaling
Solt, L. A., & May, M. J. (2008) · Immunologic Research · doi:10.1007/s12026-008-8025-1 · Cited by 284
Qin, H., Buckley, J. A., Li, X., Liu, Y., Fox, T. H., Meares, G. P., Yu, H., Yan, Z., Harms, A. S., Li, Y., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4658-15.2016 · Cited by 274
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 270
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Ros-Bernal, F., Hunot, S., Herrero, M. T., Parnadeau, S., Corvol, J.-C., Lu, L., Alvarez-Fischer, D., Carrillo-de Sauvage, M. A., Saurini, F., Coussieu, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017820108 · Cited by 231
“Selective inhibition ofNF-κBactivity was found to inhibit glial-associated neuroinflammation and DN loss in MPTP-treated mice (31); thus, NF-κB may be crucially involved in PD-associated neurodegeneration.”
BackgroundKim, S., Sato, Y., Mohan, P. S., Peterhoff, C., Pensalfini, A., Rigoglioso, A., Jiang, Y., & Nixon, R. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.97 · Cited by 212
Zecca, L., Wilms, H., Geick, S., Claasen, J.-H., Brandenburg, L.-O., Holzknecht, C., Panizza, M. L., Zucca, F. A., Deuschl, G., Sievers, J., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0361-7 · Cited by 205
Dutta, D., Jana, M., Majumder, M., Mondal, S., Roy, A., & Pahan, K. (2021) · Nature Communications · doi:10.1038/s41467-021-25767-1 · Cited by 195
Self-citationInflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175
“Moreover inhibiting NF-κ B in mice significantly protected dopamine neurons against MPTP toxicity (Ghosh et al., 2007).”
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171
Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156
Rangasamy, S. B., Jana, M., Roy, A., Corbett, G. T., Kundu, M., Chandra, S., Mondal, S., Dasarathi, S., Mufson, E. J., Mishra, R. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96209 · Cited by 139
Self-citationChandra, S., Jana, M., & Pahan, K. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0054-18.2018 · Cited by 134
“Mice were anesthetized with ketamine–xylazine injectables and perfused with PBS, followed by dissection of half of the brain from each mouse for biochemical assays and half for immunohistochemistry (Ghosh et al., 2007; Khasnavis et al., 2014).”
MethodSelf-citationEffect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse
Singh, S. S., Rai, S. N., Birla, H., Zahra, W., Kumar, G., Gedda, M. R., Tiwari, N., Patnaik, R., Singh, R. K., & Singh, S. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00757 · Cited by 125
Fluoxetine protects neurons against microglial activation-mediated neurotoxicity
Zhang, F., Zhou, H., Wilson, B. C., Shi, J.-S., Hong, J.-S., & Gao, H.-M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70066-9 · Cited by 123
Natural Products as a Potential Modulator of Microglial Polarization in Neurodegenerative Diseases
Jin, X., Liu, M.-Y., Zhang, D.-F., Zhong, X., Du, K., Qian, P., Gao, H., & Wei, M.-J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104253 · Cited by 109
Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease
Hou, Y., Li, X., Liu, C., Zhang, M., Zhang, X., Ge, S., & Zhao, L. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111376 · Cited by 101
Maatouk, L., Compagnion, A.-C., Sauvage, M.-A. C.-D., Bemelmans, A.-P., Leclere-Turbant, S., Cirotteau, V., Tohme, M., Beke, A., Trichet, M., Bazin, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04569-y · Cited by 95
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases
Thapa, K., Khan, H., Sharma, U., Grewal, A. K., & Singh, T. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118975 · Cited by 92
Inflammasome assembly in neurodegenerative diseases
Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83
Bassani, T. B., Vital, M. A. B. F., & Rauh, L. K. (2015) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20150057 · Cited by 78
Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity
Teismann, P., Sathe, K., Bierhaus, A., Leng, L., Martin, H. L., Bucala, R., Weigle, B., Nawroth, P. P., & Schulz, J. B. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.006 · Cited by 75
“Different factors have been linked to the induction of inflammation and in PD pathogenesis, one of those being the nuclearfactor-kappaB (NF-B) (Dehmer et al., 2004; Ghosh et al., 2007; Hunot et al., 1997; Hunot et al., 1999).”
Fang, X., Tian, P., Zhao, X., Jiang, C., & Chen, T. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14694 · Cited by 72
Fang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70
Inflammation as common link to progressive neurological diseases
Dias-Carvalho, A., Sá, S. I., Carvalho, F., Fernandes, E., & Costa, V. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03628-8 · Cited by 60
Rangasamy, S. B., Dasarathi, S., Pahan, P., Jana, M., & Pahan, K. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9808-3 · Cited by 49
“Briefly, half brains were incubated in 4% paraformaldehyde (w/v) followed by 30% sucrose overnight at 4 °C. Brains were then embedded, sectioned (30 μm thick), and processed for tyrosine hydroxylase (TH) staining as described previously (Benner et al. 2004; Ghosh et al. 2007).”
InfluentialSelf-citationAzadi, S., Yazdanpanah, M. A., Afshari, A., Alahdad, N., Chegeni, S., Angaji, A., Rezayat, S. M., & Tavakol, S. (2024) · Journal of Tissue Engineering · doi:10.1177/20417314241303818 · Cited by 24
Metadata
- Authors
- Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-11-20
- Volume
- 104
- Issue
- 47
- Pages
- 18754-18759
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1969999276
- Cited by
- 438
- References
- 34
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.